Literature DB >> 2568886

Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients.

S Nanbara1, S Arinaga, T Akiyoshi.   

Abstract

The effect of mitomycin C administration on the generation of cytotoxic cells, induced by in vitro activation of peripheral blood mononuclear cells (PBM) with interleukin-2, was studied in patients with various carcinomas. The ability of PBM to generate lymphokine-activated killer (LAK) cell activity against Raji cell targets was significantly augmented 5 and 7 days after a single intravenous dose of 12 mg/m2 mitomycin C, when compared to that of PBM obtained before mitomycin C injection. Further, LAK cell activity against autologous tumor cells was also significantly increased after the drug administration. The distribution of lymphocyte subsets exhibited a significant increase in the percentage of CD3+ cells after injection, with the elevation of the CD4/CD8 ratio. Furthermore, the proportion of the CD4+ Leu8+ subpopulation, which identifies inducers of suppression, was significantly reduced. Thus, the decrease in the proportion of suppressor-inducer subsets of PBM might be at least partially, responsible for the augmented generation of LAK cells after mitomycin C administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568886     DOI: 10.1007/BF00199210

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

1.  In vitro selective effect of melphalan on human T-cell populations.

Authors:  S Ben-Efraim; L Komlos; J Notmann; J Hart; I Halbrecht
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

2.  In vitro tumor cell killing by peritoneal macrophages from mitomycin C-treated rats.

Authors:  T Ogura; H Shindo; O Shinzato; M Namba; T Masuno; T Inoue; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

3.  Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes.

Authors:  S Hinuma; H Onda; K Naruo; Y Ichimori; M Koyama; K Tsukamoto
Journal:  Biochem Biophys Res Commun       Date:  1982-11-30       Impact factor: 3.575

4.  Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer.

Authors:  D Berd; H C Maguire; M J Mastrangelo
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

5.  Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients.

Authors:  S Arinaga; T Akiyoshi; H Tsuji
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

6.  Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.

Authors:  D Berd; M J Mastrangelo
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

7.  Rapid enumeration of T lymphocytes by a flow-cytometric immunofluorescence method.

Authors:  S H Ip; C W Rittershaus; K W Healey; C C Struzziero; R A Hoffman; P W Hansen
Journal:  Clin Chem       Date:  1982-09       Impact factor: 8.327

8.  Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice.

Authors:  H Shindo; T Ogura; T Masuno; S Hayashi; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

9.  The human mixed lymphocyte-tumor cell interaction test. I. Positive autologous lymphocyte proliferative responses can be stimulated by tumor cells as well as by cells from normal tissues.

Authors:  E A Grimm; B M Vose; E W Chu; D J Wilson; M T Lotze; A A Rayner; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

10.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  8 in total

1.  Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C.

Authors:  S Arinaga; N Karimine; K Takamuku; S Nanbara; H Inoue; R Abe; D Watanabe; H Matsuoka; H Ueo; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

2.  The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer.

Authors:  T Akiyoshi; S Arinaga; S Nanbara; N Karimine; H Inoue; K Takamuku; R Abe; D Watanabe; M Nagamatsu; H Matsuoka
Journal:  Jpn J Surg       Date:  1990-05

3.  Mitomycin C directly augments the expression of HLA-DR antigen in a gastric carcinoma cell line.

Authors:  H Inoue; M Adachi; S Arinaga; H Ueo; T Akiyoshi
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

4.  Glycosidically bound sialic acid levels as a predictive marker of postoperative adjuvant therapy in gastric cancer.

Authors:  K Ogoshi; Y Kondoh; T Tajima; T Mitomi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Paradoxical enhancement of interleukin-2-mediated cytotoxicity against K562 cells by addition of a low dose of methotrexate.

Authors:  T Nakarai; Y Ueno; Y Ueno; S Koizumi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.

Authors:  Z Gazit; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

7.  Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C.

Authors:  S Arinaga; N Karimine; M Adachi; H Inoue; S Nanbara; T Asoh; H Ueo; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

8.  Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration.

Authors:  H Inoue; M Adachi; N Karimine; S Arinaga; H Ueo; D Korenaga; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.